Wolfram Jung
About
Wolfram Jung is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology.
According to data from OpenAlex, Wolfram Jung has authored 41 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pathology and Forensic Medicine and 15 papers in Immunology. Recurrent topics in Wolfram Jung's work include Lymphoma Diagnosis and Treatment (15 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and CAR-T cell therapy research (8 papers). Wolfram Jung is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and CAR-T cell therapy research (8 papers). Wolfram Jung collaborates with scholars based in Germany, Netherlands and United Kingdom. Wolfram Jung's co-authors include Michael Pfreundschuh, Christoph Renner, Ulrich Dührsen, Volker Diehl, Hermann Einsele, Bernd Metzner, Uğur Şahin, Wolfram Klapper, Marcel Reiser and Joerg Hasford and has published in prestigious journals such as Science, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Wolfram Jung
39 papers receiving 1.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Wolfram Jung Germany | 17 | 823 | 821 | 489 | 401 | 379 | 41 | 1.7k | ||
| Martine E.D. Chamuleau Netherlands | 21 | 586 0.7× | 713 0.9× | 660 1.3× | 275 0.7× | 325 0.9× | 103 | 1.6k | ||
| William Townsend United Kingdom | 22 | 897 1.1× | 877 1.1× | 375 0.8× | 371 0.9× | 365 1.0× | 68 | 1.8k | ||
| SJ Horning United States | 18 | 1.0k 1.2× | 884 1.1× | 316 0.6× | 286 0.7× | 418 1.1× | 39 | 1.7k | ||
| Christoph Nerl Germany | 16 | 887 1.1× | 552 0.7× | 639 1.3× | 256 0.6× | 630 1.7× | 34 | 1.8k | ||
| Stephanie Sasse Germany | 23 | 753 0.9× | 819 1.0× | 624 1.3× | 299 0.7× | 153 0.4× | 48 | 1.6k | ||
| Max S. Topp Germany | 15 | 485 0.6× | 795 1.0× | 334 0.7× | 294 0.7× | 120 0.3× | 36 | 1.3k | ||
| Tycel Phillips United States | 22 | 956 1.2× | 899 1.1× | 367 0.8× | 142 0.4× | 554 1.5× | 149 | 1.6k | ||
| TC Meeker United States | 11 | 438 0.5× | 405 0.5× | 341 0.7× | 341 0.9× | 349 0.9× | 16 | 1.2k | ||
| Jan Maciej Zaucha Poland | 20 | 428 0.5× | 443 0.5× | 448 0.9× | 155 0.4× | 374 1.0× | 137 | 1.7k | ||
| Johannes Duell Germany | 18 | 571 0.7× | 1.3k 1.6× | 415 0.8× | 482 1.2× | 202 0.5× | 72 | 1.7k |
Countries citing papers authored by Wolfram Jung
Since
Specialization
Citations
This map shows the geographic impact of Wolfram Jung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfram Jung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfram Jung more than expected).
Fields of papers citing papers by Wolfram Jung
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Wolfram Jung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfram Jung. The network helps show where Wolfram Jung may publish in the future.
Co-authorship network of co-authors of Wolfram Jung
This figure shows the co-authorship network connecting the top 25 collaborators of Wolfram Jung. A scholar is included among the top collaborators of Wolfram Jung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfram Jung. Wolfram Jung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shumilov, Evgenii, Lewis J. Levien, Wolfram Jung, et al.. (2024). Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning. Leukemia & lymphoma. 66(4). 668–679.
2.
Hasenkamp, Justin, et al.. (2023). Low incidence and morbidity of Epstein‐Barr virus reactivation following donor lymphocyte infusions. SHILAP Revista de lepidopterología. 4(2). 563–565.
3.
Straka, Christian, Hans Salwender, Stefan Knop, et al.. (2021). Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. European Journal Of Haematology. 107(5). 529–542.
4.
Buentzel, Judith, et al.. (2021). Using Instagram to Enhance a Hematology and Oncology Teaching Module During the COVID-19 Pandemic: Cross-sectional Study. JMIR Medical Education. 7(4). e30607–e30607.
5.
Buentzel, Judith, Tobias J. Legler, Justin Hasenkamp, et al.. (2021). Sarcoidosis Following Hematopoietic Stem Cell Transplantation: Clinical Characteristics and HLA Associations. Frontiers in Immunology. 12. 746996–746996.
6.
Wulf, Gerald, Justin Hasenkamp, Wolfram Jung, et al.. (2018). Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplantation. 54(6). 877–884.
7.
Tresckow, Bastian von, Stefanie Kreissl, Helen Goergen, et al.. (2018). Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. The Lancet Haematology. 5(10). e462–e473.
8.
Venkataramani, Vivek, Ali Seif Amir Hosseini, Marco H. Schulze, et al.. (2016). Intestinal Pneumatosis Associated with Tuberculosis after Allogeneic Hematopoietic Stem Cell Transplantation. Acta Haematologica. 137(1). 51–54.
9.
Hasenkamp, Justin, et al.. (2014). Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy. International Journal of Hematology. 100(5). 425–428.
10.
Kreuz, Markus, Nils Schoof, Frederike von Bonin, et al.. (2012). Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma. Clinical Cancer Research. 18(13). 3637–3647.
11.
Hasenkamp, Justin, Markus Uhrberg, Christine S. Falk, et al.. (2008). Self‐tolerance of Human Natural Killer Cells Lacking Self‐HLA‐specific Inhibitory Receptors. Scandinavian Journal of Immunology. 67(3). 218–229.
12.
Gärtner, Barbara C., Wolfram Jung, Christoph Welsch, et al.. (2006). Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. Journal of Clinical Virology. 38(2). 146–148.
13.
Schlott, Thilo, et al.. (2003). Abundant Expression of Spliced HDM2 in Hodgkin Lymphoma Cells does not Interfere with p14ARFand p53 Binding. Leukemia & lymphoma. 44(9). 1587–1596.
14.
Schlenk, R., Frank Hartmann, M. Hensel, et al.. (2002). Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. Leukemia. 16(4). 581–586.
15.
Renner, Christoph, et al.. (2000). Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody. Cancer Immunology Immunotherapy. 49(3). 173–180.
16.
Kubuschok, Boris, Wolfram Jung, Rudolf Schmits, et al.. (2000). Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: Mutated p21 ras oncogene as a model. Cancer Gene Therapy. 7(9). 1231–1240.
17.
Jung, Wolfram, Stefan Krueger, Christoph Renner, et al.. (1994). Opposite effects of the CD30 ligand are not due to CD30 mutations: Results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Molecular Immunology. 31(17). 1329–1334.
18.
Renner, Christoph, Wolfram Jung, Uğur Şahin, et al.. (1994). Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells. Science. 264(5160). 833–835.
19.
Pohl, Christoph, Ralf W. Denfeld, Wolfram Jung, et al.. (1993). CD30‐antigen‐specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of hodgkin's lymphoma. International Journal of Cancer. 54(5). 820–827.
20.
Gause, Angela, Sigrid Klein, Wolfram Jung, et al.. (1991). Increased levels of circulating interleukin‐6 in patients with hodgkin's disease. Hematological Oncology. 9(6). 307–313.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Martine E.D. Chamuleau Breakdown of academic impact, for papers by William Townsend Breakdown of academic impact, for papers by SJ Horning Breakdown of academic impact, for papers by Christoph Nerl Breakdown of academic impact, for papers by Stephanie Sasse Breakdown of academic impact, for papers by Max S. Topp Breakdown of academic impact, for papers by Tycel Phillips Breakdown of academic impact, for papers by TC Meeker Breakdown of academic impact, for papers by Jan Maciej Zaucha Breakdown of academic impact, for papers by Johannes Duell